Melanoma

Chemotherapy efficacy increased with transcription factor gene therapy

Published in Cancer Weekly, April 23rd, 2002

by Sonia Nichols, senior medical writer - Increasing the effectiveness of some chemotherapies, especially those in the topoisomerase II family, may be as easy as administering adjunctive gene therapy.

That is the belief of researchers at the University of Louisville in Kentucky, who have spent time investigating the chemosensitization properties of transcription factor E2F-1 gene therapy in melanomas treated with standard chemotherapy. In an earlier study, the investigators demonstrated that E2F-1 gene therapy stimulates apoptosis in melanoma cells. Their current research, reported in the journal of Cancer Research, builds on those earlier efforts.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-04-23)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry